NCT07205432View on ClinicalTrials.gov

Phase I Study of XTL6001 Injection in Healthy and Obese Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 13, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Weight Management in Adult Patients With Obesity or Overweight
Interventions
DRUG

XTL6001

XTL6001 is a triple-target Glucagon-like peptide-1 receptor （GLP-1R） relevant agonist, intending to manage overweight/obesity and other metabolic diseases

DRUG

Placebo

This intervention contains no active ingredients

Trial Locations (1)

100038

RECRUITING

Beijing Shijitan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Shanghai Xitaili Biomedicine Technology co., Ltd.

INDUSTRY